Xeris Biopharma Holdings, Inc. - XERS STOCK NEWS

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced on February 24, 2021, that its Compensation Committee granted stock options for 5,000 shares and restricted stock units for 9,500 shares to three new employees under its Inducement Equity Plan. This plan incentivizes new hires by offering equity awards, which are subject to conditions like continued employment. The options will vest over four years, and the company aims to simplify administering critical therapies through innovative room-temperature stable formulations, enhancing patient and healthcare experience.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present at several investor conferences in February and March 2021. The conferences include the SVB Leerink Annual Global Healthcare Conference on February 26 at 10:40 am ET, the HC Wainwright Global Life Sciences Conference on-demand starting March 9, and the Oppenheimer 31st Annual Healthcare Conference on March 16 at 11:20 am ET. Xeris specializes in ready-to-use injectable therapies, focusing on simplifying medication administration and enhancing patient experience.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) has received European Commission approval for Ogluo™ (glucagon) injection, aimed at treating severe hypoglycemia in diabetes patients aged 2 years and above. This marketing authorization covers all 27 EU countries, along with Iceland, Norway, and Liechtenstein. Xeris plans to launch Ogluo later this year, while also seeking commercialization partnerships to expand availability. The approval stems from a Phase 3 study showing comparable efficacy to Novo Nordisk’s GlucaGen HypoKit, with no major safety concerns noted.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of 16,000 non-qualified stock options to 38 new employees as part of its Inducement Equity Plan on January 27, 2021. This plan is designed to attract individuals not previously employed by Xeris, with options vesting over four years based on continued employment. Xeris specializes in developing ready-to-use injectable and infusible drug formulations through its advanced technology platforms, offering potential cost-saving and user-friendly solutions in the pharmaceutical market.

Xeris Pharmaceuticals (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the H.C. Wainwright BioConnect 2021 virtual conference from January 11-14, 2021. The presentation will provide an overview of the company's innovative drug technologies, including its proprietary XeriSol™ and XeriJect™ platforms that offer stable, ready-to-use formulations. A webcast will be available starting January 11 at 6:00 a.m. E.T. on the company's website.

Xeris aims to simplify administration of vital therapies, benefiting patients and healthcare systems.

Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) announced the grant of non-qualified stock options for 38,250 shares and restricted stock units for 35,100 shares to 7 new employees under its Inducement Equity Plan as of December 30, 2020. The options will vest over four years, either with 25% vesting after one year or 36% after 18 months, while the restricted stock units will vest in equal annual installments. This plan aims to incentivize new hires in line with NASDAQ Listing Rules. Xeris focuses on developing ready-to-use injectable medications using advanced formulation technologies.

Xeris Pharmaceuticals (Nasdaq: XERS) has entered an exclusive distribution agreement with Megapharm Ltd. for the commercialization of its Gvoke® (glucagon injection) in Israel and the Palestinian Authority. Gvoke® is recognized as the world's first ready-to-use liquid glucagon for treating severe hypoglycemia in diabetes patients aged 2 and above. Megapharm will oversee product registration and marketing, while Xeris manages manufacturing and regulatory support. Gvoke® is expected to be available in Israel in 2022, with early access for named patients starting in early 2021.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) received a positive Opinion from the European Medicines Agency’s CHMP for Ogluo™ (glucagon) for treating severe hypoglycemia in diabetes patients. A final decision on the Marketing Authorization Application is expected in Q1 2021. If approved, Ogluo could launch in select European countries in the latter half of 2021. The positive recommendation is based on a Phase 3 study showing comparable efficacy to Novo Nordisk’s GlucaGen® HypoKit®. The study involved 132 adults with type 1 diabetes, indicating no significant safety concerns.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the granting of stock options and restricted stock units to 11 new employees under its Inducement Equity Plan. On November 25, 2020, a total of 18,000 stock options and 70,200 restricted stock units were awarded, which vest over four years contingent on continued employment. This plan, designed for new hires, aims to attract and retain talent while adhering to NASDAQ rules. Xeris specializes in developing ready-to-use injectable and infusible therapies aimed at simplifying patient administration.